Arcturus therapeutics joint venture mrna manufacturing partner, arcalis, awarded $115 million in grants from the japanese government

San diego--(business wire)---- $arct #clinicaltrial--arcturus therapeutics holdings inc. (the “company”, “arcturus”, nasdaq: arct), a global late-stage clinical messenger rna medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that arcalis co., ltd., its manufacturing joint venture in japan to support the production of mrna vaccines and therapeutics, has been awarded $115 million in two separate grants from the japanes.
ARCT Ratings Summary
ARCT Quant Ranking